Coronary artery disease (CAD) has high morbidity and mortality, therefore accurate detection of CAD and atherosclerotic plaque burden is essential. Invasive coronary angiography (ICA) can confirm the presence of luminal stenosis caused by atherosclerotic plaque and is an important tool for the quantification of CAD plaque burden. However, it has many limitations. Therefore, new methods for accurate noninvasive diagnosis of CAD using genetic markers were exerted. This study aimed at evaluation of new genetic biomarkers in diagnosing CAD and determining its severity and extent, using Gensini score as a scoring model. Sixty two subjects who had undergone coronary angiography and analyzed for the presence, severity and extent of CAD using Gensini score were selected for this study. Twenty subjects had normal Gensini score, 24 subjects were with mild to moderate CAD and 18 subjects were with severe CAD. Extraction of total RNA from whole blood was done together with PCR amplification of PNPLA2, TUBA3, FTL and AHR genes and the house keeping gene GAPDH. It was found that PNPLA2 and TUBA3 were significantly lower in CAD patients and mild/moderate CAD than in controls. However, PNPLA2 was significantly higher in severe CAD than in mild/moderate CAD. M oreover, PNPLA2 gene had The highest specificity for CAD prediction of (100%), followed by TUBA3 (60%) then FTL and AHR (each 40%), and both PNPLA2 and FTL gene had the highest sensitivity for CAD diagnosis (80.95%), followed by TUBA 3 (76.19%), then AHR (71.43%). On the other hand, PNPLA2 showed the highest specificity in CAD severity prediction (83.33%), followed by TUBA3, FTL and AHR with equal specificity (each 50%), and TUBA 3 showed the highest sensitivity (66.67%) followed by PNPLA2,, FTL and AHR with equal sensitivity (each 55.56%). In conclusion, these genes are useful in prediction of CAD and CAD severity especially emphasizing PNPLA2 and TUBA3 and further studies on larger population number and other genes are recommended. 
posttranslational [14, 15, 16] and transcriptional levels (L chain (FTL)). Ferritin synthesis increases in response to iron increase [17] . Also, ferritin gene expression was found to be increased in other cases, including cell proliferation, differentiation, inflammation, and specific hormonal signals. [18] .
AHR is constitutively expressed in many adult, mammalian tissues with the highest levels of mRNA detected in liver, kidney, lung and heart. A substantial levels of expressed AHR protein could be detected in the ex vivo human peripheral blood monocytes [19] . AHR is a cytosolic transcription factor, that upon binding to its ligand, translocates into the nucleus and dimerizes with AHR Nuclear
Translocator, AHR/AHR nuclear translocator dimers bind to xenobiotic response elements (XREs) in the promoter and enhancer regions of target genes, enhancing their transcription [19, 20] .
The genes activated by AHR code for drug and xenobiotics metabolizing enzymes (e.g.
cytochrome P450 1A1) as well as for proteins involved in regulation of cell growth, differentiation, apoptosis [20] and inflammation [21] .
The aim of this work was to study the changes of these genes in the peripheral whole blood in CAD, and to evaluate the value of these possible genomic markers in diagnosing CAD and determining its severity and extent, using Gensini score as a scoring model. This is the 1 st study to evaluate these genes in CAD disease in relation to Gensini score.
MATERIALS AND METHODS

Patient selection and grouping:
Patients were recruited from those who had undergone coronary angiography in the Cardiac Catheterization Unit, Benha university hospital. Diabetes, myocardial infarction and congestive heart failure were excluded and a written informed consent was taken from all the subjects included in the study and their clinical and laboratory data were collected.
Sampling and RNA extraction
Fasting whole blood sample (2 mL) was collected in sterile EDTA-vaccutainer tubes before coronary angiography. Extraction of total RNA from the 100 μL whole blood was performed using Direct-zol™ RNA MiniPrepkit-Zymosearch-USA according to the manufacturer instructions.
Extracted RNA was evaluated for purity and quantity using nanodrop 2000 (Thermoscientific, USA). Then extracted RNA was preserved at -80°C for further processing.
Reverse transcription
Extracted RNA was reverse transcribed using high-capacity cDNA reverse transcription kit, 
Statistical analysis:
The study data were analyzed using SPSS 
Results
Clinical and demographic data
Demographic, medical and laboratory data of the study subjects are presented in table 2. Body mass index was significantly higher in the mild/moderate CAD compared to the control and severe CAD. Fasting blood glucose (FBG) was significantly higher in patients with severe CAD compared to the control and mild/moderate CAD.
Triglycerides (TGs) level was significantly higher in CAD patients compared to control. LDLcholesterol levels were significantly lower in the CAD group compared to the control and in the severe CAD compared to mild/moderate CAD, and HDL-cholesterol levels were significantly higher in the CAD group compared to the control, probably reflecting a higher use of statins [26] .
Gensini score results and correlation analysis of the Gensini score and demographic data
Gensini score results in the different studied 
Gene expression analysis results
The expression of 4 genes was analyzed including, PNPLA2, TUBA3, FTL and AHR genes. The fold change of the studied genes expression in mild/moderate CAD, severe CAD and all CAD patients compared to the control is presented in figure 1 . Moreover, the fold change of the studied genes expression in severe CAD patients compared to mild/moderate CAD patients is presented in figure 2 . In addition, AHR gene expression showed a positive significant correlation with age in the control group and with FBG in both the control and patients groups. However, it showed a negative significant correlation with blood cholesterol level in the control group.
Analysis of PNPLA2 gene expression results
PNPLA2 gene expression in the mild
Moreover, the study of the association of the expression of the four genes with the qualitative demographic data revealed that AHR was significantly higher in smokers and hypertensive patients in both the patients and control groups, otherwise, all remaining associations were nonsignificant.
Gene expression data as predictor for CAD and severity of CAD
The best cut off values for 2^-Δct of the expressed genes with the highest specificity, sensitivity, PPV and NPV for diagnosis of CAD ( table 5) and its severity (table 6) were determined and analyzed as shown in the tables.
As regards CAD diagnosis, the study revealed that PNPLA2 gene expression had the highest specificity for diagnosis of CAD (100%), followed by TUBA3 (60%) then FTL and AHR (each 40%). showed the highest specificity (83.33%), followed by TUBA3, FTL and AHR with equal specificity (each 50%), and TUBA 3 showed the highest sensitivity (66.67%)followed by PNPLA2,, FTL and AHR with equal sensitivity (each 55.56%).
Moreover, the best PPV and NPP for diagnosis of CAD or its severity were that of PNPLA2.
Discussion
Atherosclerosis is the most frequent underlying cause of CAD. It is a chronic inflammatory disease of the vessel wall which eventually leads to blood vessels obstruction [27, 28] . Understanding the process of atherogenesis is crucial for understanding the gene expression changes in CAD disease. In atherosclerosis, Plasma molecules and lipoprotein particles extravasate through the leaky and defective endothelium into the subendothelial space, where potentially atherogenic lipoproteins are retained and modified (e.g., oxidized) and become cytotoxic, proinflammatory, chemotaxic, and proatherogenic [27] . This leads to activation of of adhesion molecules and chemoattractants that recruit monocytes and T-lymphocytes, and monocytes differentiate into macrophages in the subendothelium [27, 28] . These macrophages promote plaque development by secreting many inflammatory mediators as cytokines and chemokines, which sustain the inflammatory milieu, recruit leukocytes to the vessel wall and regulate immune functions [29] . So, plaques are [30, 31, 32, 33] suggesting that PNPLA2 is anti- It was found that PPAR-γ is a transcription factor that can bind TUBA 3 promoter [12] . TUBA 3 gene expression was found to be increased in the absence of PPAR-γ in mouse endothelial cells [31] implicating that PPAR-γ is an inhibitor of TUBA3 gene expression.Since previous studies documented the expression of PPAR-γ in endothelial cells of atherosclerotic lesions and the endothelial PPAR-γ was predicted to play a protective role in atherosclerosis [31] , this may suggests that the decrease of whole blood TUBA3 gene expression in the CAD group may reflect its atheroprotective role. However, further studies have to be done before ensuring that.
We revealed that whole blood TUBA3 gene expression decreases significantly with increasing age in both control and patients group. Also, we found that whole blood TUBA3 gene expression was negatively correlated with total cholesterol and LDL-cholesterol levels in the patients group. To our knowledge, there were no studies reporting these correlations.
The 3 rd gene evaluated in this study was the FTL gene. Studies on humans revealed that increased serum ferritin, which reflects the level of total body iron stores, was found to be associated with increased risk of carotid atherosclerosis [18] and acute myocardial infarction [42] . Pang et al. (1996) reported higher expression of L-ferritin and Hferritin mRNA (10 folds) and protein in human release of inflammatory mediators [29, 47] Inflammation is known to accelerate vessel dysfunction and aging [20] . [29] . Also, there waspositive correlation between AHR expression in blood cells and vessel stiffness in healthy human subjects indicative of vascular aging [29] . All these coincides with our study detected significant increase of AHR expression with age as was also reported by Kim et al. (2005) and elevated circulating Angiotensin II and plasma endothelin-1 (ET-1) levels [55] .
To evaluate the 4 studied genes as possible biomarkersfor prediction of CAD and its severity, the best cut off values for 2^-Δct of the expressed genes with the highest specific ity, PPV and NPV for diagnosis of CAD and its severity were determined . As regards CAD diagnosis or CAD severity prediction, PNPLA2 gene expression had the best PPV and NPP suggesting its value as a potential biomarker for or prediction of CAD and its severity. However, TUBA 3 showed a less but important value in prediction of CAD severity. To our knowledge, there was no previous study that reported the performance characteristics of the studied genes in the prediction of CAD &/or its severity.
In conclusion, whole blood PNPLA2 showed the best value in prediction of CAD and/or its severity.
However, the value of TUBA3, FTL and AHR in CAD prediction and CAD severity prediction can not be ignored, and further study on larger population number is recommended. In addition, a larger genetic studies involving evaluation of more genes should be done, in order to avoid exposing the possible CAD patients to invasive coronary angiography. 
